EMIG Archives -

NICE has entered into a new dialogue with industry to highlight the benefits of its early scientific advice

It’s good to talk, NICE says to pharma industry group

https://pharmaphorum.com/views-analysis-market-access/its-good-to-talk-nice-says-to-pharma-industry-group/

NICE has announced a collaboration with an organisation representing UK life sciences, to improve communications between the cost-effectiveness

NICE aims to improve communications with UK life sciences

https://pharmaphorum.com/news/nice-aims-to-improve-communications-with-uk-life-sciences/

A survey of small-to-medium pharma companies in the UK has revealed seven out of ten have “little or

Small-to-medium pharma fear a ‘good’ Brexit won’t be achieved

https://pharmaphorum.com/views-and-analysis/small-medium-pharma-fear-good-brexit-wont-achieved/

With time running out on Brexit, companies are already making long-term decisions.

Despite progress, Brexit still threatens UK with relegation to second division

https://pharmaphorum.com/views-and-analysis/brexit-relegation-second-division/

Further consultation on proposals for repayments.

UK government to revise drug price scheme

https://pharmaphorum.com/news/uk-government-to-revise-statutory-drug-price-scheme/

The British public is still split over Brexit – but pharma is warning of potentially serious consequences if

Brexit would be a blow for UK life sciences – regulators and pharma alike

https://pharmaphorum.com/articles/brexit-would-be-a-blow-for-uk-life-sciences-regulators-and-pharma-alike/

EMIG